Welcome to our dedicated page for HJLI news (Ticker: HJLI), a resource for investors and traders seeking the latest updates and insights on HJLI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HJLI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HJLI's position in the market.
enVVeno Medical Corporation (NASDAQ:NVNO) has successfully completed its rebranding and is now trading under the ticker symbol NVNO. Formerly known as Hancock Jaffe Laboratories, the company focuses on innovative bioprosthetic solutions for venous disease treatment. The lead product, VenoValve, aims to address deep venous Chronic Venous Insufficiency (CVI), impacting over 2.4 million people in the U.S. The device is under evaluation in the SAVVE pivotal study, with data anticipated in late 2022.
Hancock Jaffe Laboratories (NASDAQ: HJLI) is set to participate in a live webinar on September 27, 2021, at 1:00 PM ET, hosted by Ladenburg Thalmann. CEO Robert Berman will discuss the Company's innovative bioprosthetic solutions aimed at treating chronic venous insufficiency (CVI). The VenoValve, Hancock Jaffe's lead product, is currently evaluated in the SAVVE pivotal study with expected data in late 2022. Participants can pre-submit questions and register for the webinar here.
Hancock Jaffe Laboratories is rebranding to enVVeno Medical Corporation effective October 1, 2021, alongside a ticker change to NASDAQ: NVNO. The company aims to streamline its focus on the treatment of venous disease, particularly advancing the VenoValve. The pivotal trial for the VenoValve, addressing deep venous Chronic Venous Insufficiency (CVI), will start enrolling patients soon. Additionally, a second product, enVVe, is set for a mid-2022 launch. Hancock Jaffe aims to meet the needs of the 2.4 million people affected by CVI in the U.S.
Hancock Jaffe Laboratories, a developer of medical devices, will host a corporate update conference call on September 21, 2021, at 4:30 p.m. ET. Management will discuss the ongoing development of VenoValve and other corporate initiatives. The call will be led by Robert Berman, CEO, and Dr. Marc Glickman, CMO. Interested parties can participate by calling (877) 407-9708 (domestic) or (201) 689-8259 (international). The live webcast will be available on Hancock Jaffe's Investors section of their website, archived for 90 days.
Hancock Jaffe Laboratories (NASDAQ:HJLI) announced a definitive agreement with Perceptive Advisors to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering. The offering includes 2,540,650 shares priced at $7.8720 per share. Gross proceeds are expected to be approximately $20 million, excluding fees. The transaction is anticipated to close around September 9, 2021, subject to customary conditions. Ladenburg Thalmann acts as the exclusive placement agent for this offering.
Hancock Jaffe Laboratories (NASDAQ: HJLI) announced promising two-year data on its VenoValve presented at the Society for Vascular Surgery Annual Meeting. Key findings include a 63% reduction in reflux, a 60% decrease in disease manifestations, and a 93% improvement in pain scores. Notably, patients with venous ulcers showed no recurrence post-treatment. The reporting period demonstrated no safety issues. The company aims to initiate the SAVVE pivotal trial within 60 days, bolstered by FDA Breakthrough Device Designation.
Hancock Jaffe Laboratories (NASDAQ:HJLI) announced that its VenoValve received Breakthrough Device Designation from the FDA, expediting its development for treating Chronic Venous Insufficiency (CVI). This condition affects approximately 2.4 million U.S. patients. The SAVVE U.S. pivotal trial is set to enroll 75 patients at 20 centers within 60 days. Initial data from a first-in-human study showed significant improvements in patients' conditions, with no major adverse events reported. The study aims to validate the device's effectiveness and safety.
Hancock Jaffe Laboratories (NASDAQ:HJLI) will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 1:00 PM ET. CEO Robert Berman will deliver the presentation, and the management team will conduct virtual one-on-one meetings for registered investors.
A live webcast of the presentation will be available on the Company's Investors page and archived for 90 days. Hancock Jaffe specializes in bioprosthetic medical devices aimed at improving cardiac and vascular health.
Hancock Jaffe Laboratories (NASDAQ: HJLI) announced positive results for its first-in-human study of the VenoValve, presented by Dr. Jorge Hernando Ulloa at the Charing Cross International Symposium. The study showed a 54% improvement in reflux, a 56% improvement in disease manifestations, and a 76% decline in pain after one year. The VenoValve is designed to treat Chronic Venous Insufficiency (CVI), affecting 2.4 million in the U.S. The FDA approved an Investigational Device Exemption for the U.S. pivotal SAVVE trial, expected to start in Q3 2021, with 75 patients enrolled across 20 centers.
Hancock Jaffe Laboratories (NASDAQ:HJLI) announced the issuance of a U.S. patent for its VenoValve, aimed at treating Chronic Venous Insufficiency (CVI). The patent, U.S. number 10,959,841, reflects the company's commitment to innovation. Additionally, the FDA approved the Investigational Device Exemption for the SAVVE study, which will enroll 75 patients across 20 centers. CVI affects approximately 2.4 million Americans, costing over $38 billion annually in medical expenses. Hancock Jaffe aims to establish the VenoValve as a new standard of care for CVI.
